B.Pharm Lab. Instruction Manuals

Pharmacology I

APHE Anatomy, Physiology, and Health Education

Pharmaceutical Analysis

Pharmacy study material

Bones and Skeleton System

Bone disease (Gout) (Rheumatoid arthritis) (Osteoarthritis) (Osteoporosis)

Cancer and music therapy

Memory of water

Dosage and monitoring tests for anti-rheumatoid drugs


Common mechanism of action

Acts by decreasing IL-1 and collagen production.

Major adverse drug reactions (ADRs)

Skin rash, metallic taste, hypogeusia, tomatitis, anorexia, nausea, vomiting, dyspepsia, glomerulonephritis.

Monitoring test

Baseline: UA, CBC with platelets, then every week for 1 month followed by every 1-2 months but in every 2 weeks if dose is changed.


Oral: 125-250 mg daily, may increase by 125-250 mg every 1-2 months; max 750 mg/day changes.


Common mechanism of action

Immunosuppressant, blocker of G2 stage of cell cycle.

Major adverse drug reactions (ADRs)

Congestive heart failure; leucopenia; poor wound healing; thrombocytopenia, anaemia.

Monitoring test

UA, CBC with platelets every week for 1 month, then every 2-4 weeks.


Oral: 1-2 mg/kg/day .

< Prev.Page   1   2   3   4  5  6   7   8   9   10  11  12   13   Next page>